Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CN-105 peptide in acute ischemic stroke
ChiCTR2600118419Phase 2Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Feb 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CN-105 in ischemic stroke (3 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Modified Rankin Scale (mRS) score shift analysis at Day 90. Started Feb 2026; status: recruiting.
02
Drugs
CN-105
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2600118419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118419.